Champions Oncology Q1 revenue rises on research services business
Champions Oncology Q1 revenue rises on research services business
Overview
US translational oncology research firm's fiscal Q1 revenue grew 8.8% yr/yr
Oncology services margin improved to 51% from 43% in prior-year period
Outlook
Company did not provide specific guidance for the current quarter or full year
Result Drivers
RESEARCH SERVICES EXECUTION - Co said improved study execution and conversion in core research services business drove higher revenue and better margins
DATA LICENSE REVENUE - Increased commercial activity around data offerings contributed to revenue growth
LOWER RADIO-LABELING COSTS - Oncology services margin improved due to higher revenue and lower third-party radiolabeling costs
Company press release: ID:nACS90xW1a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue |
| $15.23 mln |
|
Q1 Adjusted EPS |
| $0.05 |
|
Reuters Recommended Reads
Sept 8 - Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
Sept 8 - Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Sept 8 - Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)